Brittany Cote


Questions Remain Regarding PARP Inhibition in Recurrent Platinum-Sensitive Ovarian Cancer

January 11th 2021

Joshua G. Cohen, MD, FACOG, FACS, discusses the efficacy of PARP inhibitors in ovarian cancer, remaining questions regarding repeat inhibition and treatment duration, and the potential for combinations.

Investigators Take Stock of New Landscape for Metastatic HER2-Positive Breast Cancer

November 26th 2020

Breast cancer specialists discuss noteworthy data on efficacy and safety about fam-trastuzumab deruxtecan-nxki, neratinib, and tucatinib.

I-SPY2: A Revolutionary Effort to Advance Personalized Care in Breast Cancer

November 3rd 2020

Claudine J. Isaacs, MD, discusses significant advances that have been made across all different breast cancer subtypes in recent years, as well as ongoing research efforts.

Tucatinib Triplet Takes Up Residence in Third-Line Metastatic HER2+ Breast Cancer

November 2nd 2020

Elisavet Paplomata, MD, discusses the lack of standard third-line regimens for patients with metastatic HER2-positive breast cancer, especially for those with brain metastases.

Research Efforts Strive to Overcome Osimertinib Resistance in EGFR+ Lung Cancer

November 2nd 2020

Helena A. Yu, MD, discusses novel non–small cell lung cancer combinations and biomarkers that are under investigation in order to overcome osimertinib resistance

More Clinical Trials Needed to Overcome PARP Inhibitor Resistance in Ovarian Cancer

November 2nd 2020

Gottfried E. Konecny, MD, discusses potential strategies to overcome PARP resistance, future combinations with PARP inhibitors, and other unmet needs in ovarian cancer.

Shaping a New Future With Novel Therapeutics in Gynecologic Cancers

October 31st 2020

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC

October 30th 2020

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Schiffer Spotlights Potential for TKI Discontinuation in Select Patients With CML

October 28th 2020

Charles Schiffer, MD, discusses integration of TKIs, such as imatinib, into the chronic myeloid leukemia treatment paradigm.

Enzalutamide Plus ADT Improves rPFS in Metastatic Hormone-Sensitive Prostate Cancer, Regardless of Baseline PSA Levels

October 27th 2020

The addition of enzalutamide to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer improved radiographic progression-free survival, regardless of baseline prostate-specific antigen levels.